SpringWorks Therapeutics

51 articles with SpringWorks Therapeutics

• SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

  9/18/2020

  SpringWorks Therapeutics, Inc. announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.

• SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

  9/14/2020

  Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

• SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

  8/12/2020

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2020 and provided an update on recent company developments.

• SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

  8/4/2020

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Saqib Islam, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 10:20 a.m. Eastern Standard Time.

• SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors

  7/22/2020

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that it has achieved full enrollment in its Phase 3 DeFi trial evaluating nirogacestat, an investigational gamma secretase inhibitor, in adult patients with progressing desmoid tumors.

• SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma

  6/22/2020

  SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.

• BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

  6/22/2020

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib,

• SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

  6/2/2020

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that Saqib Islam, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 8:50 a.m. Eastern Standard Time.

• SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors

  5/26/2020

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

• SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

  5/12/2020

  Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

• SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

  3/18/2020

  SpringWorks Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,087, directed to nirogacestat, the Company’s lead product candidate in development for patients with desmoid tumors and as a combination therapy for patients with multiple myeloma.

• SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

  3/12/2020

  Dosed the First Patients in the Phase 2b ReNeu Clinical Trial of Mirdametinib for Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors

  2/27/2020

  MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) announced Phase 1 clinical trial.

• SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

  2/18/2020

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020

• Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

  1/13/2020

  Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy

• SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/6/2020

  SpringWorks Therapeutics, Inc. announced that Saqib Islam, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020 at 1:30 p.m. Pacific Standard Time.

• Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate at the ASH Annual Meeting

  12/9/2019

  STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that its collaborator, GlaxoSmithKline, presented data evaluating SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat (formerly PF-03084014), alone and in combination with GlaxoSmithKline’s investigational anti-B-cell mat

• SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

  11/12/2019

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced financial results for the third quarter ended September 30, 2019, and provided an update on recent company developments.

• 

  Clinical Catch-Up: October 21-25

  10/28/2019

  Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.